PLRZ · Polyrizon Ltd. · Documents

Polyrizon completed enrollment and randomization of 120 participants across five U.S. clinical sites for its NASARIX allergic rhinitis study; 144 individuals were screened, and remaining activities precede a clinical data readout.

Polyrizon Ltd. announced on Oct. 05, 2026 that it filed a new U.S. divisional patent application titled “Mucoadhesive Polymers for Nasal Drug Delivery,” assigned U.S. Patent Application No. 19/823,285.

Polyrizon Ltd. registered up to 404,166 ordinary shares for resale by a selling shareholder, issuable upon exercise of September 2026 warrants. Polyrizon receives no resale proceeds but may receive approximately $4.0 million from cash warrant exercises.

Polyrizon Ltd. reported cash and cash equivalents of 8,410 and net loss of (1,424) for the six months ended June 30, 2026. On September 4, 2026, it closed an offering for gross proceeds of $4,000 thousand.